If you’ve been following major brand launches recently, you’ll have noticed a clear shift: there is less and less talk of simply ‘boosting collagen’ or ‘combating glycation’, whilst the spotlight is increasingly turning to nuclear anti-ageing—terms such as DNMT1, CDK1, DNA methylation and the epigenetic clock, which sound like they’ve been plucked from a molecular biology paper, are now appearing frequently in cosmetic products.

 

This is not merely a conceptual upgrade; rather, the logic behind anti-ageing has genuinely reached a stage where ‘entering the nucleus’ has become essential.

 

I. The Three-Step Leap in Anti-Ageing: The Inevitable Evolution from the Skin to the Nucleus

 

Looking back at the path of skincare and anti-ageing, the trajectory is actually very clear:

Anti-ageing 1.0: Focus on the Extracellular Matrix (ECM)

The emphasis was on replenishing and stimulating collagen, elastin and glycosaminoglycans. The approach was to ‘repair damaged skin and provide support where it has sagged’, but the integrity of the ECM depends on whether fibroblasts are active and whether their cell cycle is functioning properly—addressing the consequences rather than the root cause.

 

Anti-ageing 2.0: Cellular and Organelle Function

Attention shifts to mitochondrial energy supply (ATP, Sirt3, AMPK), oxidative stress (Nrf2) and inflammation (NF-κB, SASP). The approach evolves to ‘preventing cells from becoming too exhausted or too inflamed’, but why do cells go on strike? Often, the answer lies within the cell nucleus: epigenetic drift, cell cycle arrest and abnormal DNA damage response.

 

Anti-ageing 3.0: The Cell Nucleus as the Clock Centre

Directly targeting epigenetics (DNA methylation/DNMT1), the cell cycle engine (CDK1/Cyclin) and nuclear membrane homeostasis (Lamin B1).

 

A 2024 review by the SenNet Consortium published in *Nature Reviews Molecular Cell Biology* clearly states that cellular ageing begins with cell cycle arrest and culminates in the accumulation of senescent cells; whilst the order of the cell cycle is strictly regulated by the nuclear CDK–Cyclin complex, methylases such as DNMT1 govern the ‘epigenetic clock’ that governs gene expression. Only those capable of moderately calibrating this nuclear programme stand a chance of delaying skin ageing at its root.

This is why Chanel, in collaboration with the University of Vienna since 2012, ultimately identified red camellia as a source for upregulating CDK1 and Lamin B1; Beiersdorf, in 2024, introduced Epicelline® (dihydro-myricetin), targeting DNA methylation and the Age Clock—international giants have, almost in unison, staked their claims on ‘nuclear core targets’, essentially casting their votes for the same biological reality: the root cause of epidermal ageing lies in the ageing of the cell nucleus.

II. What are the two ‘1s’ at the heart of the battle within the cell nucleus?

Among the nuclear targets currently proven to be highly correlated with skin anti-ageing, one cannot avoid a pair of ‘top-tier 1s’:

 

1. DNMT1: The knob of the epigenetic clock

 

DNA methylation is one of the core markers of epigenetics. With advancing age, methylation patterns become disrupted, leading to the erroneous silencing of ‘youthful genes’ and the abnormal activation of ‘ageing genes’, resulting in a shift in the Age Clock.

DNMT1 (DNA methyltransferase 1) is responsible for maintaining methylation during replication; its overactivity or dysregulation exacerbates epigenetic drift. Research has confirmed that moderate inhibition of DNMT1 can promote the restoration of baseline epigenetic patterns, partially resetting the ageing clock and leading to improvements in regeneration and homeostasis.

 

2. CDK1: The engine driving the cell cycle from G2 to M

The CDK1–Cyclin B1 complex is key to propelling cells into mitosis. As the skin ages, CDK1 activity declines, causing basal layer stem cells to become stuck in the G0/G1 or G2/M phases. This leads to cell cycle arrest and slowed renewal, resulting in the successive appearance of wrinkles, sagging and a dull complexion.

Cutting-edge data shows that activating CDK1 can eliminate UVA-induced G1 arrest, restore the proportion of cells in the S/G2 phase, and restart the youthful rhythm of ‘renewal’.

A consensus emerges from the strategies of industry leaders:

The next phase of anti-ageing lies in entering the cell nucleus to regulate the clock and restart the cell cycle. Only one question remains—who will develop this ‘nuclear-level mechanism’ into a stable, usable cosmetic ingredient capable of penetrating the skin?

 

III. Pomegranate Time Factor: Using Fermentation to Incorporate ‘Urosapogenin A + Nuclear Targets’ into Formulations

Here, we must mention Pomemit® Pomegranate Time Factor developed by Nanohealth, which perfectly aligns with the two emerging trends of ‘nuclear anti-ageing’ and ‘biotransformation’.

1. Why pomegranate → urolithin A?

Pomegranate polyphenols (such as delphinidin and ellagic acid) possess potent antioxidant properties, but their bioavailability—whether taken orally or applied topically—is extremely low. Furthermore, they require conversion by gut microbiota into urolithin A, yet most people’s gut flora lacks the strains necessary for efficient conversion.

Urolithin A is currently one of the few naturally occurring prebiotics proven through research to activate mitochondrial autophagy, extend cell lifespan and improve photoageing. It has also been found to inhibit UVA-induced G1 arrest, upregulate CDK1, activate Nrf2 and protect the nuclear membrane protein Lamin B1—it inherently possesses the potential for cross-level regulation from ‘organelles to the cell nucleus’.

 

2. Mimetic Bioconversion: ‘Cultivating bacteria to produce UA’ for you in vitro

 

Pomemit® utilises enzyme engineering and fermentation engineering to screen for highly efficient Lactobacillus strains, which direct the conversion of pomegranate juice polyphenols into urolithin A at a concentration of >2% (total polyphenols 2.0–2.5%) in vitro. This approach circumvents variations in human gut microbiota, ensuring a stable supply of anti-ageing postbiotics. 

3. Key ‘Double 1’ Core Data (In Vitro)

Third-party biological reports indicate that, in in vitro models:

DNMT1 mRNA: –24.5% (at a concentration of 0.00975%, moderately inhibiting DNA methylation, suggesting intervention in the epigenetic clock) 

CDK1 mRNA: +157% (at a concentration of 0.039%, significantly upregulating the expression of the cell cycle engine and restarting cell cycle progression) 

Epidermal thickness: +28.7%, collagen density: +19.9% (at 0.3%, in a photoageing model, promoting proliferation and reducing wrinkles) 

Melanin content:  At equivalent skin-lightening efficacy, the required dosage is only 1/2778th that of β-arbutin

These data may not constitute definitive conclusions, but they do at least bring the ‘pomegranate → UA → nuclear targets’ pathway to the fore at the cellular and tissue levels.

 

4. 28-day human trial: Dual improvement in texture and tone

32 participants aged 30–60, using a 0.3% pomegranate-derived time-reversing pigment sample; after 28 days: 

Firmness: +46.40%

 

Radiance: +39.27%, ITA° +3.09°, b* -3.12% (brightening and reduction of sallowness)

 

Pore area: -17.91%, crow’s feet area: -8.58%

 

2-hour sebum secretion: –32.38% (oil control and skin refinement)

 

Conclusion

Ingredients such as Pomemit® Pomegranate Time Factor, which combine ‘fermented prebiotics with dual first-class nuclear targets’, do not derive their value from replacing retinol, peptides or boswellic acid, but rather from integrating the final link in the anti-ageing chain—the correction of intracellular programmes—into the formulation architecture.

 

Nuclear anti-ageing may not be a panacea, but it is undoubtedly the answer that currently comes closest to explaining ‘why we age’. Whoever can establish a firm footing in this field through robust data and methodology will hold the key to Anti-Ageing 3.0.